https://www.selleckchem.com/pr....oducts/ddr1-in-1.htm
Despite advances in care, the 5 year overall survival for patients with relapsed and or metastatic sarcoma remains as low as 35%. Currently, there are no biomarkers available to assess disease status in patients with sarcomas and as such, disease surveillance remains reliant on serial imaging which increases the risk of secondary malignancies and heightens patient anxiety. Here, for the first time reported in the literature, we have enumerated the cell surface vimentin (CSV+) CTCs in the blood of 92 sarcoma pediatric and adolesce
Like
Comment
Share
